登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
NK Cell Therapy for Malignant Solid Brain Tumors
ClinicalTrials.gov 上登记的一项胶质瘤开放试验,由北京大学第三医院牵头,本站收录的另外 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07552233,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 70 岁;性别:不限
登记记录的入选字段
At least one evaluable lesion with previous biopsy or pathohistologic confirmation of malignant central nervous system tumor, with imaging suggestive of continued progression or recurrence after comprehensive treatment
入选标准第 2 条
Patients who completed radiotherapy or systemic therapies (including temozolomide/bevacizumab or other agents) for at least 4 weeks prior to enrollment. All prior treatment-related toxicities should be defined as ≤ grade 1 (except for toxicities such as alopecia or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 6.0)
入选标准第 5 条
Fertile women must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception (hormonal or barrier method of birth control or abstinence) during the clinical trial and for 6 months after the last cell infusion; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
入选标准第 20 条
Karnofsky Performance Status (KPS) ≥ 60%
入选标准第 3 条
White blood cell count (WBC) ≥ 3 x 10\^9/L
入选标准第 8 条
Absolute neutrophil count (ANC) > 1 x 10\^9/L
入选标准第 9 条
Hemoglobin (Hb) ≥ 90 g/L
入选标准第 10 条
Platelet (PLT) ≥ 80×10\^9/L
入选标准第 11 条
Albumin transaminase (ALT) \& albumin transaminase (AST) < 1.5 × institutional upper limit of normal (ULN)
入选标准第 12 条
Serum creatinine (Cr) < 1.5 x institutional ULN
入选标准第 13 条
Total bilirubin < 1.5 x institutional ULN
入选标准第 14 条
PT \& PTT ≤ 1.25 x institutional ULN
入选标准第 15 条
Life expectancy > 4 weeks, and must be able to undergo an MRI with contrast
入选标准第 4 条
Active hepatitis B or C virus, HIV infection, or other untreated active infection
排除标准第 1 条
Pregnant and lactating women
排除标准第 2 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07552233,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Male or female, age 18-70 years old (both ends included) At least one evaluable lesion with previous biopsy or pathohistologic confirmation of malignant central nervous system tumor, with imaging suggestive of continued progression or recurrence after comprehensive treatment Karnofsky Performance Status (KPS) ≥ 60% Life expectancy > 4 weeks, and must be able to undergo an MRI with contrast Patients who completed radiotherapy or systemic therapies (including temozolomide/bevacizumab or other agents) for at least 4 weeks prior to enrollment. All prior treatment-related toxicities should be defined as ≤ grade 1 (except for toxicities such as alopecia or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 6.0) Dexamethasone dose ≤ 4 mg/day or equivalent corticosteroid dose, or no dexamethasone administered Must have adequate organ and marrow function as defined below: White blood cell count (WBC) ≥ 3 x 10\^9/L Absolute neutrophil count (ANC) > 1 x 10\^9/L Hemoglobin (Hb) ≥ 90 g/L Platelet (PLT) ≥ 80×10\^9/L Albumin transaminase (ALT) \& albumin transaminase (AST) < 1.5 × institutional upper limit of normal (ULN) Serum creatinine (Cr) < 1.5 x institutional ULN Total bilirubin < 1.5 x institutional ULN PT \& PTT ≤ 1.25 x institutional ULN No obvious hereditary diseases Normal cardiac function with left ventricular ejection fraction >55% No bleeding and coagulation disorders Absence of positive blood cultures for bacteria, fungus, or virus within 48-hours prior to NK cell infusion and/or there aren't any indications of meningitis Fertile women must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception (hormonal or barrier method of birth control or abstinence) during the clinical trial and for 6 months after the last cell infusion; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately Signed, written informed consent排除标准:Exclusion Criteria:
Active hepatitis B or C virus, HIV infection, or other untreated active infection Pregnant and lactating women Participants with organ failure Participants with a chronic disease requiring immunologic or hormonal therapy Participants with an allergy to immunotherapy and related cells Participants with uncontrolled intercurrent illness Participants with psychiatric illness/social situations that would limit compliance with study requirements Participants with a history of organ transplantation or who are awaiting organ transplantation
引自 ClinicalTrials.gov, NCT07552233, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07552233,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。